WARSAW

OrthoPediatrics Corp. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance

Retrieved on: 
월요일, 5월 6, 2024
Total, International, Investment, Research, Elective surgery, Growth, Webcast, Event, Pega, Marketing, Orthopediatrics, OPSB, Deformity, Scoliosis

U.S. revenue for the first quarter of 2024 was $34.3 million, a 44% increase compared to $23.8 million for the same period last year, representing 77% of total revenue.

Key Points: 
  • U.S. revenue for the first quarter of 2024 was $34.3 million, a 44% increase compared to $23.8 million for the same period last year, representing 77% of total revenue.
  • International revenue for the first quarter of 2024 was $10.4 million, a 33% increase compared to $7.8 million for the same period last year, representing 23% of total revenue.
  • Trauma and Deformity revenue for the first quarter of 2024 was $33.3 million, a 42% increase compared to $23.4 million for the same period last year.
  • Scoliosis revenue was $10.2 million, a 44% increase compared to $7.1 million for the first quarter of 2023.

OrthoPediatrics Corp. Receives “Breakthrough Device” Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis

Retrieved on: 
목요일, 5월 2, 2024
EOS, FDA, Public, Safety, Food, De novo, Surgeon, Elective surgery, Pathology, Breakthrough, Spine, Patient, Diagnosis, Deformity, Elli, Scoliosis

eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology.

Key Points: 
  • eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology.
  • eLLi will allow surgeons a new alternative to address deformity of the growing spine with an advanced technology that will complement our efforts to build a platform of EOS technologies.
  • We are proud to have an expert design team comprised of surgeons who have dedicated their careers to treating these unique patients.
  • David Bailey, OrthoPediatrics’ President & CEO, commented, “Receiving the Breakthrough Device designation from the FDA is a great achievement for our team.

Financial Institutions, Inc. Announces First Quarter 2024 Results

Retrieved on: 
목요일, 4월 25, 2024
Benefit, Common equity, Sale, NFP, Common, Federal Reserve, Investment, Nature, Bank, TCE, Tier 1 capital, As a service, Insurance, Financial institution, Risk management, Environment, Computer, Income tax, Risk-weighted asset, Acquisition, Community Reinvestment Act, Loss, Marketing, Bank statement, Five Star Bank, Community, Growth, Earnout, Video game

Net income was $2.1 million in the first quarter of 2024, compared to $9.8 million in the fourth quarter of 2023 and $12.1 million in the first quarter of 2023.

Key Points: 
  • Net income was $2.1 million in the first quarter of 2024, compared to $9.8 million in the fourth quarter of 2023 and $12.1 million in the first quarter of 2023.
  • First quarter 2024 financial results were negatively impacted by the Company's previously disclosed deposit-related fraud event, which was the primary driver of noninterest expense variances from the linked and year-ago periods.
  • Net interest margin was 2.78% in the current quarter and the fourth quarter of 2023, and 3.09% in the first quarter of 2023.
  • The effective tax rate was 14.7% for the first quarter of 2024, 34.5% for the fourth quarter of 2023, and 18.7% for the first quarter of 2023.

OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
월요일, 4월 22, 2024
Orthopediatrics, Elective surgery, Webcast, Event

WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes.

Key Points: 
  • WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes.
  • OrthoPediatrics will host a conference call on Tuesday, May 7, 2024, at 8:00 a.m.
  • ET to discuss the results.
  • The webcast will be available for replay for at least 90 days after the event.

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)

Retrieved on: 
목요일, 4월 4, 2024
ICSS, Patient, Orthopediatrics, Hospital, Rib, Cadaver, Surgeon, CME, Scoliosis, Adolescent idiopathic scoliosis, Elective surgery, Nursing

WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it will attend the 8th Annual International Children’s Spine Symposium (ICSS), which will take place April 5th and 6th in Denver, Colorado.

Key Points: 
  • WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it will attend the 8th Annual International Children’s Spine Symposium (ICSS), which will take place April 5th and 6th in Denver, Colorado.
  • The meeting, put on by the Armstrong Children’s Orthopedic Alliance, offers a comprehensive program of lectures given by an outstanding, international faculty and cadaver labs centered on the cervical spine, lumbo-sacral junction, neuromonitoring, and various aspects of scoliosis.
  • We consider ICSS to be an interactive forum that allows us to engage with pediatric orthopedic fellows and attending surgeons and train on the latest technologies and surgical techniques.
  • The symposium is always well attended and receives great feedback from attendees, so I am looking forward to this being another productive event.”

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
수요일, 4월 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

Financial Institutions, Inc. Announces Sale of the Assets of SDN Insurance Agency to NFP

Retrieved on: 
월요일, 4월 1, 2024
8-K, Financial institution, Five Star Bank, PC, Growth, Form, Bank, Sale, LLP, Security (finance), NFP, Insurance

As part of the transaction, the SDN team joins NFP, including President William E. Gallagher.

Key Points: 
  • As part of the transaction, the SDN team joins NFP, including President William E. Gallagher.
  • “In the nearly 10 years since we entered the insurance space, it has proven to be a valuable line of business that supported revenue diversification.
  • SDN is a full-service insurance agency serving business and personal insurance customers.
  • “In its 100-year history, SDN has established itself as a well-respected partner to commercial and personal insurance customers throughout Western New York,” said Mr. Gallagher.

OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
화요일, 3월 26, 2024
Conference, Elective surgery

WARSAW, Ind., March 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • WARSAW, Ind., March 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference.

Financial Institutions, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call

Retrieved on: 
월요일, 3월 25, 2024
Financial institution, Five Star Bank

WARSAW, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (NASDAQ: FISI) (the “Company”), the parent company of Five Star Bank, SDN Insurance Agency, LLC, and Courier Capital, LLC, will release results for the first quarter ending March 31, 2024 after the market closes on April 25, 2024.

Key Points: 
  • WARSAW, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (NASDAQ: FISI) (the “Company”), the parent company of Five Star Bank, SDN Insurance Agency, LLC, and Courier Capital, LLC, will release results for the first quarter ending March 31, 2024 after the market closes on April 25, 2024.
  • Management will host an earnings conference call and audio webcast on April 26, 2024 at 8:30 a.m. Eastern Time.
  • The call will be hosted by Martin K. Birmingham, President and Chief Executive Officer, and W. Jack Plants II, Chief Financial Officer and Treasurer.
  • Within the United States, listeners may also access the call by dialing 1-833-470-1428 and providing the access code 916080.